FOUR-YEAR STUDY OF ENTECAVIR EFFICACY AND SAFETY IN NUCLEOS(T)IDE-NAIVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS
[ X ]
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Sestre Milosrdnice Univ Hospital
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Entecavir is a guanosine analogue with activity against hepatitis B virus. The aim of this 4-year trial was to evaluate entecavir treatment in nucleos(t)ide-naive HBeAg-positive chronic hepatitis B patients. Forty-nine patients received entecavir and nine of them withdrew from the trial at the end of week 96. The initial mean value of alanine aminotransferase was 79.4 +/- 41.5 IU/L, and at the end of the 4-year study period, 90% of patients had alanine aminotransferase values within the normal range. At week 96, 91.7% of patients had HBV DNA <300 copies; at month 48, 90% of patients had HBV DNA <50 IU/mL. HBeAg loss was recorded in 7.1% of patients at week 96 and in 12.5% at month 48. The rate of HBeAg seroconversion was 4.8% at week 96 and 7.5% at month 48. The rate of HBsAg seroconversion was 2.1% at week 96 and 2.5% at month 48. Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy.
Açıklama
Anahtar Kelimeler
Guanine - Therapeutic Use, Hepatitis B, Chronic, Antiviral Agents - Therapy
Kaynak
Acta Clinica Croatica
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
53
Sayı
1
